PitchSend

Investor Presentaiton

Oncology: KEYTRUDA continues to drive exceptional growth • KEYTRUDA sales of $6.3B increased 17% year-over-year, driven by global uptake in earlier stage cancers and continued strong global demand from metastatic indications - In the U.S., growth of 14% reflects strong utilization across metastatic indications and earlier stage cancers, such as TNBC KEYTRUDA (pembrolizumab) Injection 100 mg - Ex-U.S., 22% increase driven by uptake in earlier stage cancers, including high-risk early- $5.4B +26% stage TNBC and adjuvant RCC, as well as increased demand in advanced RCC and certain types of H&N cancer $4.5B +21% Growth rates exclude the impact of foreign exchange. $6.3B +17% 3Q21 3Q22 3Q23 MERCK 11

View entire presentation